132 related articles for article (PubMed ID: 27067552)
1. Reversibility of renal dysfunction after discontinuation of tenofovir.
Cha A; Besignano-Long AR; Rothberger N; Shah B
J Am Pharm Assoc (2003); 2016; 56(3):280-3. PubMed ID: 27067552
[TBL] [Abstract][Full Text] [Related]
2. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
Estébanez M; Bernardino JI; Serrano L; Pérez-Valero I; Zamora FX; Montes-Ramírez ML; González-García JJ; Arribas JR
Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):29-32. PubMed ID: 25735716
[TBL] [Abstract][Full Text] [Related]
3. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
Kalemeera F; Godman B; Stergachis A; Rennie T
Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
[No Abstract] [Full Text] [Related]
4. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
5. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
6. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
[TBL] [Abstract][Full Text] [Related]
7. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
[TBL] [Abstract][Full Text] [Related]
8. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
9. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
11. Effect of tenofovir containing ART on renal function in patients with moderate/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia.
Kalemeera F; Godman B; Stergachis A; Rennie T
Pharmacol Res Perspect; 2023 Feb; 11(1):e00681. PubMed ID: 36585791
[TBL] [Abstract][Full Text] [Related]
12. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K; Makanani B; Tierney C; Fowler MG; Moodley D; Theron G; Nyakudya LH; Tomu M; Fairlie L; George K; Heckman B; Knowles K; Browning R; Siberry GK; Taha TE; Stranix-Chibanda L;
BMC Infect Dis; 2022 Jul; 22(1):634. PubMed ID: 35858874
[TBL] [Abstract][Full Text] [Related]
13. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S; Hamzah L; Campbell LJ; Hill T; Fisher M; Leen C; Gilson R; Walsh J; Nelson M; Hay P; Johnson M; Chadwick D; Nitsch D; Jones R; Sabin CA; Post FA;
J Infect Dis; 2014 Aug; 210(3):363-73. PubMed ID: 24585896
[TBL] [Abstract][Full Text] [Related]
14. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
15. Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
Kyaw NT; Harries AD; Chinnakali P; Antierens A; Soe KP; Woodman M; Das M; Shetty S; Zuu MK; Htwe PS; Fernandez M
PLoS One; 2015; 10(8):e0135188. PubMed ID: 26301416
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
17. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
[TBL] [Abstract][Full Text] [Related]
18. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
